Clinical Trial Update: Tipranavir in Patients With Progressive, Systemic HIV-1 Disease Who Have Failed or Are Intolerant to Currently Approved Treatments for HIV Infection

View source ↗

Summary

Tipranavir has received marketing approval for HIV infection in patients with progressive systemic HIV-1 disease who have failed or are intolerant to other appr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Aptivus (tipranavir)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: HIV Infections | Status: APPROVED_FOR_MARKETING